These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 6331074)

  • 1. Aging brain and dopamine receptors: abnormal regulation by CCK-8 of 3H-spiperone labeled dopamine receptors in striatal membranes.
    Agnati LF; Fuxe K; Battistini N; Benfenati F
    Acta Physiol Scand; 1984 Mar; 120(3):465-7. PubMed ID: 6331074
    [No Abstract]   [Full Text] [Related]  

  • 2. Are striatal [3H]spiperone radioreceptor assays indicative of multiple dopamine receptor interactions?
    Clements-Jewery S; Robson PA
    Neuropharmacology; 1981 Dec; 20(12B):1295-8. PubMed ID: 7322304
    [No Abstract]   [Full Text] [Related]  

  • 3. Selective modulation of 3H-spiperone labeled 5-HT receptors by subchronic treatment with the ganglioside GM1 in the rat.
    Agnati LF; Benfenati F; Battistini N; Cavicchioli L; Fuxe K; Toffano G
    Acta Physiol Scand; 1983 Feb; 117(2):311-4. PubMed ID: 6869038
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
    Bennett JP; Wooten GF
    Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum.
    Zahniser NR; Dubocovich ML
    J Pharmacol Exp Ther; 1983 Dec; 227(3):592-9. PubMed ID: 6655559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of a partial ergoline with dopamine receptors in vivo and in vitro.
    Fuxe K; Goldstein M; Agnati LF; Köhler C; Lew JY; Okada K
    Acta Physiol Scand; 1983 Feb; 117(2):303-5. PubMed ID: 6869037
    [No Abstract]   [Full Text] [Related]  

  • 7. Differential modulation by CCK-8 and CCK-4 of [3H]spiperone binding sites linked to dopamine and 5-hydroxytryptamine receptors in the brain of the rat.
    Agnati LF; Fuxe K; Benfenati F; Celani MF; Battistini N; Mutt V; Cavicchioli L; Galli G; Hökfelt T
    Neurosci Lett; 1983 Feb; 35(2):179-83. PubMed ID: 6304577
    [No Abstract]   [Full Text] [Related]  

  • 8. Striatal dopamine receptor function in morphine-tolerant dependent rats: influence of hypothalamic peptides.
    Bhargava HN
    NIDA Res Monogr; 1984 Mar; 49():320-6. PubMed ID: 6148693
    [No Abstract]   [Full Text] [Related]  

  • 9. Estimation of the apparent affinity of the striatal dopamine receptors for the radioligand[3H]spiperone [( 3H]spiroperidol).
    Hruska RE
    J Neurosci Res; 1984; 12(4):571-81. PubMed ID: 6512888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postsynaptic location of acrylamide-induced modulation of striatal 3H-spiroperidol binding.
    Hong JS; Tilson HA; Agrawal AK; Karoum F; Bondy SC
    Neurotoxicology; 1982 Jul; 3(1):108-12. PubMed ID: 6890181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of cholecystokinin octapeptide on rat striatal 3H spiperone binding.
    O'Shaughnessy C; Poat JA; Turnbull MJ
    Biochem Pharmacol; 1985 Aug; 34(15):2675-7. PubMed ID: 4015708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D2 receptor dissociation constant for spiperone: identical values using 3H-labeled agonist or 3H-labeled antagonist.
    Seeman P; Grigoriadis D
    Biochem Pharmacol; 1985 Nov; 34(22):4065-6. PubMed ID: 4062976
    [No Abstract]   [Full Text] [Related]  

  • 13. Cataleptogenic doses of morphine suppress 3H-spiroperidol binding to striatal membranes.
    Golembiowska-Nikitin K; Pilc A; Vetulani J
    Naunyn Schmiedebergs Arch Pharmacol; 1982 May; 319(2):140-1. PubMed ID: 7202125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA; Marsh CL
    Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple daily amphetamine administration decreases both [3H]agonist and [3H]antagonist dopamine receptor binding.
    Sibley DR; Weinberger S; Segal DS; Creese I
    Experientia; 1982 Oct; 38(10):1224-5. PubMed ID: 6890464
    [No Abstract]   [Full Text] [Related]  

  • 16. [Relation between brain D2-dopamine receptors and 3H-spiperone binding sites of intact lymphocytes].
    Noguchi-kuno SA; Nakata C; Nishitani H
    Rinsho Shinkeigaku; 1983 Sep; 23(9):814-8. PubMed ID: 6232031
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of dopamine interactions with [3H]-spiperone binding sites on rat corpus striatum membranes [proceedings].
    Howlett DR; Nahorski SR
    Br J Pharmacol; 1979 Jul; 66(3):468P-469P. PubMed ID: 526752
    [No Abstract]   [Full Text] [Related]  

  • 18. Cholecystokinin peptides in vitro modulate the characteristics of the striatal 3H-N-propylnorapomorphine sites.
    Agnati LF; Celani MF; Fuxe K
    Acta Physiol Scand; 1983 May; 118(1):79-81. PubMed ID: 6312748
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic proglumide increases [3H]spiperone binding in the rat brain.
    Bean AJ; Baldy WJ; Martin GE
    Eur J Pharmacol; 1985 Oct; 117(1):97-101. PubMed ID: 4085545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cation regulation differentiates specific binding of [3H]sulpiride and [3H]spiperone to rat striatal preparations.
    Theodorou AE; Hall MD; Jenner P; Marsden CD
    J Pharm Pharmacol; 1980 Jun; 32(6):441-4. PubMed ID: 6106685
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.